Key PointsROR1 is overexpressed in pediatric BCP-ALL and T-ALL cells and can be resistant to induction therapy.Treatment with ROR1 bispecific Teng can redu
OffLabel Disclosure:. Di Stefano:Sebia: Current Employment. Mouktadi:Sebia: Current Employment. Bonifay:Sebia: Current Employment. Rougé Dubroc:Sebia: Curr
In this issue of Blood, Jiang and colleagues1 report that platelet NOD-like receptor family pyrin domain containing 6 (NLRP6) is critical for the preventio
July 2025 | ASH Clinical News | American Society of Hematology July 2025 Health Care Harmed With President Trump’s cuts to research funding and restrictions…
In this issue of Blood, Wang et al1 describe a way forward to novel small molecule remedies for sickle cell disease (SCD). The authors employed…
In this issue of Blood, an international group of experts coordinated by the European Research Initiative on CLL (ERIC) reports consensus recommendations o
In this edition of Blood, Palma et al1 identify a novel set of genes whose expression is sufficient to confer hematopoietic stem cell (HSC) fate…
Long-term survival (LTS) in multiple myeloma (MM), defined as survival of ≥10 years post-diagnosis following a single line of therapy, is an increasingly o
Abstract. Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple myeloma, form immune synapses between T-cell surface marker CD3
In this issue of Blood, an international group of experts coordinated by the European Research Initiative on CLL (ERIC) reports consensus recommendations o
Key PointsHNRNPC, an essential RNA-binding protein and m6A reader, coordinates oncogenic transcription and cell metabolism in T-ALL.Patients with T-ALL pre
